Healthcare
Eli Lilly and Company(LLY)
Data coverage status · 6 need attention
Quote through 2026-08-05T13:30:00Z · Stale
Quote synced 2026-08-05T21:29:31.193582Z
Daily bars through 2026-08-03 · Stale
Daily bars synced 2026-08-04T22:41:42.599122Z
Fundamentals through 2025-12-31 · Stale
Fundamentals synced 2026-08-05T21:09:45.46753Z
Forecasts: Stale
Forecasts synced 2026-04-28T14:30:39.333549Z
Ownership through 2025-12-31 · Stale
Ownership synced 2026-08-05T21:09:45.46753Z
Short interest through 2025-12-31 · Stale
Short interest synced 2026-08-05T21:09:45.46753Z
News through 2026-08-03T21:08:39Z · Delayed
News synced 2026-08-03T22:32:21.818502Z
Company profile: Delayed
Company profile synced 2026-05-01T16:05:05.652154Z
Regular-session price
Offline$1,168.78($1,123.00 after-hours, +0.50%)
+4.76% regular session
1Y Change
+45.73%
Window
Aug 5, 2025 → Aug 4, 2026
- Market Cap
- $915.33B
- P/E
- 34.3
- Trailing
- 52W Range
- $623.78 - $1,249.45
- Volume
- 5.50M
- 2.4x RVOL
Investment Snapshot
Valuation, growth, profitability, catalysts, and benchmark context.
1D
+4.8%
1M
-7.0%
6M
+0.8%
YTD
+3.3%
1Y
+45.7%
- Market Cap
- $915.33B
- NYSE
- P/E
- 34.3
- Trailing valuation
- Revenue Growth
- +44.7%
- TTM growth
- EPS Growth
- +95.5%
- TTM earnings growth
- Operating Margin
- 45.6%
- TTM profitability
- Forward P/E
- —
- Waiting on consensus EPS
- Next Earnings
- Sep 4, 2026
- In 30 days
- 52W Position
- 87%
- $623.78 - $1,249.45
- Volume
- 2.4x
- 5.50M shares latest
- Benchmark
- +22.90 pts
- vs SPY over 1Y
- Dividend
- 0.6%
- Last ex-date May 15, 2026
Coverage: 250 bars · Aug 5, 2025 → Aug 4, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eli Lilly and Company (LLY) is a Healthcare stock with listed on NYSE. The stock last traded around $1168.78 and up 45.7% across the available one-year price window (Aug 5, 2025 → Aug 4, 2026). Baseline metrics include revenue growth of +44.7%, EPS growth of +95.5%, a dividend yield of 0.6%. What stands out right now is revenue +44.7%, EPS +95.5%, free cash flow +1339.5% with operating margin 45.6% and ROIC 32.1%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 34.3 and price/sales 12.7. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines LLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+44.7% vs +7.6% peer median
Operating Margin
Above sector median
+45.6% vs +19.7% peer median
P/E
Below sector median
34.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q2 2026 was reported on Apr 30, 2026 with an EPS surprise of +25.9%.
The operating story is still moving forward
Revenue is running at +44.7% and EPS at +95.5%, with operating margin around 45.6%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 4, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Delta | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 Apr 30, 2026 | +25.9% | +3.1% | +4.3% | +18.2% |
Q1 2026 Feb 4, 2026 | +9.1% | -7.8% | -8.3% | -11.2% |
Q4 2025 Oct 30, 2025 | +19.2% | +2.2% | +11.0% | +27.3% |
Benchmark Edge
LLY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
Mixed setup vs SPY
LLY is 22.90 pts ahead over the shared 1Y window.
LLY had 14.18 pts deeper max drawdown than SPY.
LLY beat SPY in 1 of 2 calendar years shown and trailed in 1.
LLY
+45.73%
Normalized return
SPY
+22.83%
S&P 500
Excess Return
+22.90 pts
Relative to SPY
LLY Max Drawdown
-23.31%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LLY and SPY.
| Year | LLY | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +3.32% | +12.67% | -9.35 pts | SPY |
| 2025 | +40.97% | +9.40% | +31.57 pts | LLY |
Company Overview
Eli Lilly and Company
New York Stock Exchange
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- Leadership
- David A. Ricks
- IPO Date
- Jun 1, 1972
- Employees
- 47.0k
- Street Address
- Lilly Corporate Center
- Mailing
- Indianapolis, IN, 46285
- Region
- Indianapolis, IN, US
- Reporting Currency
- USD
- Investor Line
- 317 276 2000
- Last Updated
- May 1, 2026
Statistics & Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 34.3
- EV/EBITDA
- 28.8
- Price/Sales
- 12.7
- Price/Book
- 27.8
Growth
- Revenue
- +44.7%
- EPS
- +95.5%
- Free Cash Flow
- +1339.5%
Profitability
- Gross Margin
- 83.0%
- Operating Margin
- 45.6%
- Net Margin
- 31.7%
- ROE
- 101.3%
- ROIC
- 32.1%
Balance Sheet
- Debt/Equity
- 1.39
- Current Ratio
- 0.65
Ownership & Float
- Float
- 889.32M
- Short Interest
- 1.1%
- Insider Owned
- 0.2%
- Institutional Owned
- 85.1%
Earnings Reports
Latest News
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.